Likelihood of LVDD is Predictive of Carfilzomib-Induced Cardiovascular AEs in R/R Multiple Myeloma
In this retrospective study, researchers investigated whether assessing left ventricular diastolic function in patients receiving carfilzomib for relapsed or refractory multiple myeloma improved risk of cardiovascular adverse events.